synthet
triazol
nucleosid
ribavirin
tribavirin
virazol
broad
spectrum
antivir
activ
includ
dna
well
rna
virus
ribavirin
close
resembl
guanosin
convert
intracellularli
mono
di
triphosph
deriv
inhibit
viral
induc
enzym
involv
viral
nucleic
acid
synthesi
dna
virus
ribavirin
activ
herp
simplex
viru
hepat
b
viru
among
rna
virus
good
activ
observ
hepat
c
viru
orthomyxovirus
paramyxovirus
arenavirus
bunyavirus
although
activ
hiv
vitro
vivo
ribavirin
wide
use
treatment
hiv
infect
oral
ribavirin
success
use
treatment
lassa
fever
crimean
congo
hemorrhag
fever
combin
therapi
interferon
alfa
hepat
c
infect
sever
public
suggest
enhanc
efficaci
combin
interferon
alfa
ribavirin
compar
monotherapi
interferon
alfa
also
evid
retreat
combin
may
succeed
control
elimin
viremia
monotherapi
fail
although
combin
may
lead
increas
advers
reaction
normal
associ
interferon
alfa
dyspnea
pharyng
pruritu
nausea
insomnia
anorexia
doubt
oral
ribavirin
add
overal
toxic
combin
caus
hemolyt
anemia
usual
mild
ribavirin
well
absorb
oral
given
aerosol
form
treatment
respiratori
syncyti
viru
rsv
infect
immunocompromis
patient
cardiopulmonari
abnorm
infant
receiv
mechan
ventil
advers
reaction
interferon
ribavirin
treatment
hepat
c
infect
review
sinc
ribavirin
almost
alway
use
combin
interferon
difficult
know
whether
advers
event
druginduc
due
one
mani
case
author
even
discuss
problem
often
attribut
suppos
advers
reaction
interferon
case
withdraw
one
agent
provid
evid
case
may
clue
exampl
case
skin
pigment
site
inject
interferon
advers
reaction
may
presum
due
interferon
type
ii
betweentheey
advers
reaction
one
case
hemolyt
anemia
attribut
interferon
rather
ribavirin
patient
previous
taken
cours
interferon
without
advers
reaction
presum
infer
patient
sensit
previou
cours
systemat
review
case
drug
use
togeth
individu
also
yield
use
inform
case
pneumon
patient
treat
interferon
ribavirin
attribut
interferon
similarli
case
ocular
myasthenia
pleural
effus
cataract
interferon
blame
previou
case
found
associ
ribavirin
alon
case
advers
event
persist
time
withdraw
pegyl
interferon
ribavirin
long
half
peginterferon
cite
possibl
explan
weak
evid
case
case
may
imposs
tell
whether
advers
event
druginduc
due
one
drug
combin
observ
studi
combin
interferon
ribavirin
caus
advers
reaction
patient
coinfect
hepat
c
hiv
hepat
c
howev
one
seri
patient
unexpect
advers
reaction
record
one
subject
develop
pancreat
four
other
develop
asymptomat
hyperamylasemia
disappear
withdraw
take
concomit
didanosin
secondli
lactat
concentr
increas
slightli
two
individu
take
stavudin
signific
weight
loss
kg
averag
within
month
may
anoth
advers
effect
result
interact
ribavirin
hiv
nucleosid
analogu
mechan
benefici
effect
ad
ribavirin
interferon
fulli
understood
ribavirin
monotherapi
effect
hepat
c
howev
ad
ribavirin
interferon
increas
number
patient
virolog
respons
although
also
increas
number
advers
event
benefit
harm
ad
ribavirin
interferon
patient
chronic
hepat
c
consid
therapi
start
hepat
c
viru
hcv
rna
kinet
studi
day
patient
nine
six
genotyp
respect
week
patient
genotyp
respect
treatment
ribavirin
pegyl
interferon
patient
sustain
virolog
respons
svr
significantli
pronounc
mean
log
declin
baselin
hcv
rna
amount
week
compar
patient
fail
achiev
sustain
respons
wherea
differ
day
patient
log
reduct
hcv
rna
amount
day
posit
predict
valu
sustain
virolog
respons
wherea
week
best
time
point
predict
later
nonrespons
patient
fail
achiev
log
fall
patient
genotyp
log
fall
hcv
rna
amount
posit
predict
valu
sustain
virolog
respons
week
week
correspond
neg
predict
valu
patient
genotyp
respect
patient
one
withdrew
treatment
second
dose
pegyl
interferon
four
withdrew
prematur
one
treatment
week
unknown
reason
one
week
psychiatr
reason
one
patient
withdrew
week
arthralgia
dosag
reduct
requir
three
patient
thrombocytopenia
neutropenia
three
other
dosag
ribavirin
reduc
anemia
combin
treatment
interferonalfa
ribavirin
chronic
hepat
induc
virolog
respons
suffici
rate
despit
partial
effect
improv
biochem
respons
superior
interferonalfa
monotherapi
patient
chronic
hepat
n
treat
interferon
million
u
three
timesweek
subcutan
ribavirin
mgday
oral
month
followup
least
month
rang
compens
liver
diseas
rais
transaminas
activ
hepat
viru
rna
posit
baselin
genotyp
analys
show
hepat
viru
genotyp
hepat
b
viru
genotyp
biochem
respons
eight
patient
end
treatment
seven
patient
end
followup
eight
patient
end
treatment
four
end
followup
sustain
virolog
respons
flulik
symptom
gener
mild
moder
patient
two
patient
requir
shortterm
dosag
reduct
mu
leukopenia
thrombocytopenia
two
patient
drop
hemoglobin
manag
reduct
dosag
ribavirin
two
prospect
open
trial
hivhepat
c
viru
coinfect
individu
receiv
peginterferon
ribavirin
week
respond
defin
fall
hepat
c
viru
rna
least
log
unit
patient
develop
psychiatr
advers
reaction
respond
advers
reaction
anemia
advers
reaction
eye
also
frequent
respond
suggest
dosag
may
high
enough
nonrespond
postul
risk
increas
sever
recurr
hepat
c
viru
infect
live
donor
liver
transplant
ldlt
patient
prevent
therapi
studi
patient
receiv
interferonalpha
ribavirin
month
transplant
month
first
neg
hcv
rna
test
observ
without
therapi
month
group
therapi
continu
least
month
hcvrna
test
remain
posit
group
remov
protocol
could
continu
therapi
month
advers
reaction
could
start
therapi
earli
death
eight
patient
remov
protocol
three
die
two
could
start
poor
gener
condit
nine
patient
assign
group
six
group
sustain
virolog
respons
ratio
signific
differ
group
histolog
activ
score
year
therapi
detail
given
advers
reaction
eight
patient
withdrawn
pegyl
interferon
ribavirin
use
success
treat
fulmin
hepat
c
infect
mild
selflimit
advers
reaction
hemolyt
anemia
highdos
ribavirin
outbreak
sever
acut
respiratori
syndrom
toronto
associ
high
rate
advers
event
anemia
ci
hypomagnesemia
ci
bradycardia
ci
risk
anemia
hypomagnesemia
bradycardia
attribut
ribavirin
respect
author
conclud
use
highdos
ribavirin
appropri
treatment
infecti
diseas
ribavirin
proven
clinic
efficaci
context
clinic
trial
state
ribavirin
use
empir
treatment
viral
syndrom
unknown
origin
patient
take
ribavirin
peginterferon
nine
patient
report
flulik
symptom
four
develop
anemia
three
pancytopenia
three
gastrointestin
symptom
one
paresthesia
pruritu
tremor
resolv
end
treatment
retrospect
audit
patient
take
ribavirin
peginterferon
alfa
follow
advers
event
report
fatigu
fever
weight
loss
irrit
bodi
pain
two
larg
random
placebocontrol
comparison
interferon
alon
combin
interferon
plu
ribavirin
publish
initi
treatment
chronic
hepat
c
patient
randomli
assign
receiv
standarddos
interferon
alon
combin
ribavirin
mgday
oral
depend
bodi
weight
week
expect
dosag
reduct
anemia
necessari
patient
take
combin
therapi
none
treat
interferon
alon
dyspnea
pharyng
pruritu
rash
nausea
insomnia
anorexia
advers
effect
report
often
combin
therapi
ribavirin
patient
whose
chronic
hepat
relaps
therapi
interferon
alon
patient
random
receiv
standarddos
interferon
alon
combin
ribavirin
mgday
oral
depend
bodi
weight
month
dosag
reduct
anemia
requir
patient
assign
combin
therapi
none
assign
interferon
alon
case
initi
therapi
studi
dyspnea
nausea
rash
significantli
common
patient
treat
combin
interferon
ribavirin
ribavirin
mgkgday
plu
interferon
alfa
teenag
compar
interferon
alon
differ
dropout
rate
viral
clearanc
achiev
patient
took
combin
treatment
versu
took
monotherapi
advers
event
similar
two
group
mild
hemolyt
anemia
end
first
month
children
took
ribavirin
four
moder
sever
hemolysi
two
stop
take
ribavirin
sever
hemolysi
patient
thalassemia
warrant
withdraw
ribavirin
within
month
metaanalysi
trial
total
patient
ribavirin
plu
interferon
significantli
reduc
morbid
plu
mortal
ci
significantli
improv
sustain
viral
clearanc
treatmentna
patient
rr
ci
relaps
rr
ci
nonrespond
rr
ci
gave
follow
number
need
treat
benefici
effect
nnt
b
reduct
mortalitymorbid
ci
clear
hcvrna
improv
histolog
respons
analysi
also
gave
inform
increas
toxic
ad
ribavirin
follow
number
need
treat
one
harm
occur
nnt
h
anemia
leukopenia
rash
pruritu
insomnia
dermat
dyspnea
fatigueweak
dri
skin
anorexianausea
dyspepsia
pharyng
cough
also
valu
nnt
h
dosag
reduct
stop
treatment
treatment
peginterferon
ribavirin
achiev
complet
clinic
respons
patient
hepat
crelat
vascul
complet
clinic
respons
correl
erad
viru
requir
shorter
treatment
period
previous
report
interferon
alfa
plu
ribavirin
month
short
cours
well
toler
although
one
patient
withdrew
neutopenia
cough
occur
commonli
patient
take
combin
interferon
ribavirin
compar
interferon
alon
four
patient
develop
chronic
cough
take
peginterferon
ribavirin
chronic
hepat
c
infect
capsaicin
cough
challeng
test
show
cough
reflex
sensit
significantli
increas
treatment
cough
resolv
within
week
withdraw
reflex
sensit
improv
prospect
studi
spirometri
week
patient
take
ribavirin
peginterferon
chronic
hepat
c
report
dyspnea
associ
chang
forc
vital
capac
fvc
forc
expiratori
volum
second
fev
ratio
fev
fvc
man
develop
progress
dyspnea
month
progress
cough
follow
frequent
abund
elimin
bronchial
cast
symptom
resolv
day
withdraw
caus
found
man
chronic
hepat
c
given
peginterferon
ribavirin
week
develop
dyspnea
extrem
exert
episod
cough
follow
volumin
expector
consist
larg
piec
cm
length
mucuslik
materi
mimick
bronchial
cast
given
prednison
partial
improv
later
peginterferon
ribavirin
withdrawn
respiratori
complaint
complet
resolv
systemat
review
case
report
pneumon
patient
receiv
peginterferon
ribavirin
chronic
hepat
c
infect
case
trace
pneumon
present
combin
fever
dyspnea
cough
fatal
case
exclus
peginterferon
headach
frequent
advers
reaction
combin
therapi
ribavirin
interferon
howev
headach
report
earli
control
trial
ribavirin
monotherapi
chronic
hepat
c
frequenc
advers
reaction
compar
patient
treat
interferon
ribavirin
interferon
monotherapi
patient
treat
combin
therapi
chronic
hepat
c
seven
develop
new
sever
migrain
headach
two
worsen
preexist
migrain
symptom
mostli
start
delay
sever
week
month
seven
patient
migrain
improv
consider
resolv
ribavirin
withheld
dose
reduc
recurr
rechalleng
fulldos
ribavirin
causal
link
ribavirin
migrain
appear
plausibl
proven
progress
multifoc
leukoencephalopathi
hiv
neg
patient
attribut
pegyl
interferon
ribavirin
man
develop
parkinson
take
peginterferon
ribavirin
chronic
hepat
c
improv
drug
withdrawn
respond
cobeneldopa
may
coincident
man
chronic
hepat
c
relat
intraven
drug
use
develop
unilater
facial
nerv
palsi
take
ribavirin
mgday
peginterferon
week
facial
weak
persist
week
therapi
resolv
week
complet
treatment
retrospect
analysi
winr
trial
random
control
comparison
fix
versu
weightbas
ribavirin
dose
eight
patient
develop
seizur
therapi
three
gener
tonicclon
seizur
seizur
type
unknown
five
one
patient
taken
longterm
antiepilept
drug
therapi
one
start
therapi
seizur
recurr
none
recurr
seizur
complet
treatment
retin
vein
thrombosi
associ
peginterferon
alfa
ribavirin
man
chronic
hepat
c
visual
complic
prospect
analys
patient
take
ribavirin
peginterferon
alfa
chronic
hepat
c
retinopathi
report
patient
retin
hemorrhag
signific
visual
impair
eight
four
patient
respect
withdraw
therapi
six
patient
result
resolut
two
spanish
patient
develop
transient
visual
disturb
due
retinopathi
treatment
ribavirin
peginterferon
alfa
one
case
symptom
resolv
spontan
despit
continu
treatment
symptom
resolv
withdraw
perman
visual
loss
due
retinopathi
also
occur
man
took
ribavirin
peginterferon
alfa
week
multipl
cottonwool
spot
bilater
visual
acuiti
fail
improv
month
withdraw
man
took
ribavirin
peginterferon
alfa
chronic
hepat
c
develop
branch
retin
arteri
central
retin
vein
occlus
acut
bilater
retin
detach
occur
two
patient
take
ribavirin
peginterferon
alfa
withdraw
agent
highdos
glucocorticoid
led
partial
improv
one
case
inflammatori
retin
detach
vogtkoyanagiharada
diseas
occur
woman
concomit
hypertens
took
ribavirin
mg
weekli
interferon
visual
symptom
improv
partli
withdraw
drug
follow
highdos
oral
glucocorticoid
man
develop
ischem
optic
neuropathi
take
ribavirin
mgday
peginterferon
alfa
month
visual
acuiti
field
defect
fail
improv
despit
withdraw
interferon
therapi
high
dose
system
steroid
notabl
featur
report
visual
defect
resolv
resolv
partli
withdraw
suggest
either
drug
caus
effect
irrevers
may
case
retin
detach
effect
coincident
due
drug
black
man
histori
substanc
abus
develop
chronic
hepat
c
given
interferon
ribavirin
month
develop
bilater
cotton
wool
spot
retin
hemorrhag
left
eye
retinopathi
persist
sever
month
resolv
eye
treatment
withdrawn
visual
complaint
chang
visual
acuiti
clear
drug
respons
advers
reaction
case
sensorineur
hear
loss
attribut
interferon
plu
ribavirin
yearold
man
develop
vertigo
tinnitu
bilater
hear
loss
postur
intoler
tempor
relat
administr
pegyl
interferon
ribavirin
chronic
hepat
c
viral
infect
bilater
highfrequ
sensorineur
hear
loss
vertigo
saccad
intrus
fixat
smooth
visual
pursuit
supin
hypertens
orthostat
hypotens
inadequ
reflex
compensatori
cardiovascular
respons
hemolyt
anemia
audiometri
show
chang
suggest
damag
cochlear
outer
hair
cell
withdraw
therapi
result
rapid
clinic
resolut
mild
residu
hear
loss
tinnitu
transient
sensorineur
hear
loss
describ
two
patient
chronic
hepat
c
took
ribavirin
peginterferon
alfa
man
develop
unilater
sensorineur
hear
loss
therapi
ribavirin
interferon
week
despit
withdraw
agent
recoveri
month
fact
hear
loss
unilater
resolv
drug
withdraw
suggest
drugrel
similar
case
report
albeit
case
unilater
effect
suggest
drug
may
respons
patient
chronic
hepat
c
genotyp
infect
given
peginterferon
ribavirin
sensit
salt
sweet
tast
impair
week
bitter
tast
describ
unpleas
appetit
also
impair
cognit
dysfunct
studi
patient
chronic
hepat
c
treatment
peginterferon
alfa
ribavirin
week
standard
dose
cognit
perform
significantli
impair
week
compar
control
patient
chronic
hepat
c
take
peginterferon
ribavirin
aspect
attent
impair
week
dysfunct
resolv
week
withdraw
author
hypothes
may
irrevers
damag
dorsolater
prefront
cortex
anterior
cingul
cortex
prospect
studi
patient
hepat
cposit
took
longterm
ribavirin
peginterferon
alfa
without
escitalopram
psychiatr
symptom
low
mood
anxieti
impair
concentr
hostil
depress
patient
respect
without
escitalopram
lower
incid
took
concomit
antidepress
prospect
studi
depress
symptom
patient
take
ribavirin
peginterferon
alfa
rise
averag
beck
depress
inventori
score
particularli
patient
subclin
depress
symptom
treatment
yearold
man
develop
sever
depress
suicid
ideat
take
ribavirin
mgday
interferon
month
fail
improv
despit
antidepress
therapi
symptom
improv
withdraw
agent
patient
take
peginterferon
ribavirin
hepat
c
infect
men
women
fulfil
diagnost
criteria
dsmiv
major
depress
common
women
somat
symptom
common
includ
myalgia
headach
joint
pain
nauseavomit
abdomin
pain
bout
palpit
patient
noncirrhot
chronic
hepat
c
given
interferon
plu
ribavirin
week
develop
thyroid
dysfunct
compar
control
await
treatment
women
higher
risk
rr
hypothyroid
common
hyperthyroid
retrospect
studi
patient
receiv
interferon
ribavirin
hepat
c
infect
develop
suppress
serum
tsh
grave
diseas
transient
thyroid
develop
rais
serum
tsh
develop
perman
hypothyroid
requir
levothyroxin
women
rel
risk
thyroid
dysfunct
ci
serum
tsh
mul
posit
thyroid
peroxidas
antibodi
titer
therapi
associ
rel
risk
ci
ci
respect
combin
baselin
tsh
thyroid
peroxidas
antibodi
data
predict
progress
thyroid
dysfunct
sensit
woman
chronic
hepat
c
develop
hashimoto
thyrotoxicosi
follow
type
diabet
mellitu
addit
ribavirin
mgday
longterm
peginterferon
alfa
continu
take
agent
requir
longterm
insulin
thyroxin
replac
patient
take
ribavirin
peginterferon
alfa
develop
autoimmun
nonautoimmun
thyroid
levothyroxin
replac
requir
case
prospect
investig
incid
thyroid
disord
patient
chronic
hepat
c
treatment
ribavirin
peginterferon
thyroid
function
studi
antihcv
viral
rnaposit
patient
patient
thyroid
dysfunct
occur
within
first
week
develop
thyroid
disord
week
seven
thyroid
dysfunct
antithyroid
peroxidas
antibodi
type
diabet
mellitu
thyroid
diseas
reportedli
develop
patient
treat
combin
interferonalfa
ribavirin
chronic
hepat
c
rare
coexist
howev
condit
report
woman
anoth
case
woman
develop
type
diabet
recurr
grave
diseas
treatment
peginterferon
alfa
ribavirin
chronic
hepat
c
serum
antiglutam
acid
decarboxylas
antibodi
author
suggest
autoimmun
polyglandular
syndrom
type
iii
timedepend
dosedepend
hemolyt
anemia
eventu
associ
hyperbilirubinemia
high
reticulocyt
count
major
toxic
reaction
associ
oral
intraven
ribavirin
revers
withdraw
man
took
longterm
ribavirin
peginterferon
alfa
chronic
hepat
c
develop
autoimmun
hemolyt
anemia
week
therapi
requir
transfus
withdraw
agent
eight
children
age
year
la
cross
enceph
treat
highdos
intraven
ribavirin
mgkg
load
dose
follow
mgkg
day
mgkg
day
four
develop
hemolyt
anemia
necessit
drug
withdraw
anoth
seven
children
receiv
lower
dose
mgkg
load
dose
follow
mgkg
day
develop
hemolyt
anemia
adult
treat
ribavirin
interferon
develop
symptomat
anemia
first
week
treatment
given
erythropoietin
requir
dosag
reduct
withdraw
therapi
pure
red
cell
aplasia
also
associ
ribavirin
pegyl
interferon
alfa
well
hepat
b
c
infect
anemia
due
pure
red
cell
aplasia
report
man
took
ribavirin
mgday
peginterferon
ribavirinassoci
pure
red
cell
aplasia
fulli
revers
withdraw
man
chronic
hepat
c
infect
develop
activ
protein
c
resist
increas
factor
viii
activ
rais
fibrinogen
concentr
hyperhomocysteinemia
take
peginterferon
alfa
ribavirin
month
pulmonari
embol
hematolog
abnorm
return
normal
month
drug
withdraw
patient
take
ribavirin
plu
interferon
averag
fall
hemoglobin
gdl
patient
take
ribavirin
mgday
random
high
dose
peginterferon
week
microgramskg
week
microgramskg
week
microgramkg
week
patient
random
receiv
low
dose
microgramskg
week
three
patient
requir
reduc
dose
ribavirin
anemia
patient
nipah
viru
infect
differ
incid
advers
reaction
elect
ribavirin
treatment
refus
dose
base
recommend
use
achiev
approxim
concentr
seen
mgday
treatment
hepat
c
anemia
occur
ribavirintr
patient
number
control
patient
receiv
peginterferon
alfa
ribavirin
mean
platelet
count
baselin
l
noncirrhot
patient
n
l
cirrhosi
n
mean
fall
platelet
count
treatment
l
sever
thrombocytopenia
platelet
count
l
patient
nine
develop
platelet
count
l
instanc
bleed
patient
one
due
gastrointestin
angiodysplasia
sever
patient
without
sever
thrombocytopenia
time
minor
bleed
common
platelet
count
l
anemia
associ
peginterferon
ribavirin
thought
mix
form
ribavirininduc
hemolysi
interferoninduc
myelosuppress
howev
studi
patient
receiv
peginterferon
ribavirin
mean
hemoglobin
fell
significantli
gdl
serum
erythropoietin
respons
lower
seen
histor
control
iron
defici
mean
dosag
ribavirin
reduc
mgday
maintain
dosag
ribavirin
detail
studi
effect
ribavirin
erythrocyt
atp
content
hexos
monophosph
shunt
conduct
vitro
atp
concentr
significantli
reduc
hexos
monophosph
shunt
increas
suggest
erythrocyt
suscept
oxid
vivo
ribavirin
alon
combin
interferon
associ
signific
reduct
hemoglobin
concentr
mark
increas
absolut
reticulocyt
count
erythrocyt
nak
pump
activ
significantli
reduc
wherea
kcl
cotransport
dithiothreitolsensit
fraction
malondialdehyd
methemoglobin
concentr
increas
significantli
ribavirintr
patient
show
increas
aggreg
band
associ
significantli
increas
bind
autolog
antibodi
complement
fragment
suggest
erythrophagocyt
remov
reticuloendotheli
system
random
control
trial
highdos
interferon
plu
oral
ribavirin
month
patient
chronic
hepat
c
sequenti
effect
treatment
hemoglobin
leukocyt
platelet
record
fall
hemoglobin
lowest
concentr
record
month
treatment
group
hematolog
measur
return
normal
end
treatment
genomewid
associ
studi
patient
chronic
hepat
c
two
function
variant
itpa
gene
caus
inosin
triphosphatas
itpas
defici
protect
ribavirininduc
hemolyt
anemia
patient
polymorph
associ
reduct
hemoglobin
minor
allel
variant
protect
genomewid
studi
japanes
patient
hepat
c
viru
infect
treat
peginterferon
ribavirin
variant
locat
upstream
inosin
triphosph
pyrophosphatas
gene
chromosom
significantli
associ
treatmentinduc
anemia
sever
snp
strongli
associ
fall
hemoglobin
includ
nonsynonym
snp
anoth
snp
splice
variantrel
polymorph
japanes
popul
stratifi
analysi
base
genotyp
show
inosin
triphosph
pyrophosphatas
express
correl
fall
hemoglobin
suggest
direct
causal
variant
japanes
popul
factor
could
help
predict
hematolog
abnorm
patient
chronic
hepat
c
take
pegyl
interferon
ribavirin
studi
patient
year
develop
neutropenia
n
anemia
n
thrombocytopenia
n
genotyp
histori
hypertens
low
baselin
platelet
count
low
baselin
hemoglobin
rais
serum
creatinin
concentr
signific
factor
low
pretreat
platelet
count
dose
interferon
alfa
haptoglobin
phenotyp
suscept
factor
ribavirininduc
anemia
fall
hemoglobin
independ
dose
therapeut
rang
five
patient
chronic
hepat
c
hemodialysi
receiv
subcutan
interferon
oral
ribavirin
week
dose
ribavirin
titrat
base
hemoglobin
bone
marrow
support
erythropoietin
signific
bone
marrow
toxic
five
dose
mgday
produc
steadyst
auc
compar
obtain
mgday
histor
control
normal
renal
function
sever
anemia
possibl
due
chronic
renal
insuffici
addit
prolong
effect
ribavirin
treatment
ribavirininduc
hemolyt
anemia
recombin
human
erythropoietin
describ
patient
hemoglobin
concentr
increas
nadir
gdl
median
gdl
ribavirin
treatment
withdrawn
tongu
hyperpigment
describ
therapi
ribavirin
peginterferon
alfa
chronic
hepat
c
hyperpigment
oral
mucosa
tongu
report
caucasian
woman
hepat
c
infect
taken
peginterferon
microgramsweek
plu
ribavirin
g
day
week
tongu
discomfort
notic
irregular
black
patch
later
surfac
tongu
oral
mucosa
woman
develop
numer
asymptomat
dark
brown
macul
tongu
oral
mucosa
take
peginterferon
ribavirin
month
woman
develop
dark
brown
asymptomat
pigment
dorsum
tongu
take
peginterferon
alfa
plu
ribavirin
week
lesion
resolv
within
month
withdraw
woman
develop
lingual
hyperpigment
take
ribavirin
pegyl
interferon
hepat
c
viru
infect
dark
gray
macul
bilater
dorsolater
surfac
tongu
oral
eros
nail
cutan
abnorm
new
medic
begun
close
tempor
proxim
onset
discomfort
peginterferon
ribavirin
taken
month
man
hepat
c
took
ribavirin
peginterferon
alfa
develop
malabsorpt
histolog
serolog
investig
confirm
celiac
diseas
symptom
improv
follow
strict
glutenfre
diet
withdraw
agent
woman
hepat
c
infect
given
peginterferon
microgramsweek
ribavirin
gday
week
develop
neutropenia
l
secondari
enterocol
bowel
wall
thicken
involv
cecum
proxim
ascend
colon
respond
broadspectrum
antibiot
support
treatment
gcsf
filgastrim
liver
damag
attribut
ribavirin
interferon
yearold
woman
stabl
chronic
hepat
c
develop
fulmin
hepat
take
ribavirin
peginterferon
alfa
jaundic
clot
deterior
despit
withdraw
interferon
use
highdos
glucocorticoid
requir
liver
transplant
woman
chronic
hepat
c
took
ribavirin
interferon
week
develop
persist
abnorm
biochemistri
rais
aminotransferas
alkalin
phosphatas
gammaglutamyl
transferas
despit
remain
seroneg
hepat
c
viru
liver
biopsi
show
cirrhosi
attribut
antivir
drug
therapi
part
multicent
random
doubleblind
placebocontrol
trial
ribavirin
patient
hepat
c
viru
infect
liver
biopsi
studi
iron
deposit
increas
total
iron
deposit
preferenti
hepatocyt
occur
cours
ribavirin
deposit
appar
effect
biochem
histolog
respons
ribavirin
therapi
ribavirin
caus
hemoglobinuria
result
black
urin
irrevers
alopecia
associ
ribavirin
addit
ribavirin
interferon
therapi
may
associ
increas
risk
advers
skin
reaction
advers
cutan
event
occur
patient
take
interferon
plu
ribavirin
review
photosensit
administr
ribavirin
describ
welldocu
photoallerg
reaction
woman
take
ribavirin
interferon
alfa
provid
evid
ribavirin
potenti
photosensit
uvb
problem
may
becom
increasingli
relev
patient
chronic
hepat
c
take
combin
therapi
month
interferon
alfa
ribavirin
occasion
rash
area
drug
contact
conjunctiv
irrit
occur
aerosol
ribavirin
use
month
infant
immunodefici
pruritu
xerosi
mild
skin
erupt
eczema
lichen
planu
common
ribavirin
plu
interferon
therapi
three
case
oral
lichen
planu
worsen
treatment
chronic
hepat
c
pegyl
interferon
ribavirin
woman
develop
lichenoid
erupt
hand
take
interferon
ribavirin
day
lesion
resolv
within
week
withdraw
control
symptom
mostli
requir
sustain
therapi
moder
potent
potent
topic
glucocorticoid
combin
baselin
emolli
throughout
combin
treatment
period
howev
occasion
report
mark
erythemat
maculopapular
erupt
start
day
start
combin
therapi
although
form
skin
reaction
probabl
cell
mediat
rare
emphas
occur
earli
treatment
evolv
stevensjohnson
syndrom
dermat
occur
patient
given
ribavirin
pegyl
interferon
half
patient
clinic
symptom
within
first
month
combin
treatment
first
sign
typic
appear
distant
site
peginterferon
inject
complain
gener
itch
xerosi
erythematopapulomicrovesicular
lesion
predilect
extensor
surfac
limb
skin
site
expos
friction
seven
skin
biopsi
superfici
dermal
perivascular
inflamm
spongiosi
parakeratosi
erythrocyt
extravas
spars
keratinocyt
necrosi
extens
inflamm
interfac
variabl
last
occur
clinic
sever
case
two
patient
develop
specif
skin
sign
differ
eczemalik
pattern
describ
one
patient
gener
eczemat
skin
chang
eventu
develop
malar
hypertrichosi
lanuginosa
bullou
skin
lesion
milia
back
hand
lead
diagnosi
porphyria
cutanea
tarda
one
patient
develop
bullou
erupt
histolog
featur
acantholyt
dermat
nonspecif
immunohistolog
profil
five
case
meyerson
syndrom
halo
dermat
benign
eczemat
rash
around
preexist
nevu
report
treatment
hepat
c
syndrom
report
ribavirin
condit
resolv
withdraw
therapi
wellestablish
associ
hepat
c
viru
infect
porphyria
cutanea
tarda
howev
thought
ribavirin
increas
risk
increas
iron
overload
via
hemolysi
two
case
porphyria
cutanea
tarda
report
treatment
ribavirin
interferon
report
cutan
sarcoidosi
associ
pegyl
interferon
alfa
plu
ribavirin
treatment
sarcoid
granulomata
attribut
ribavirin
peginterferon
alfa
woman
took
ribavirin
peginterferon
alfa
month
develop
sarcoid
granuloma
site
previou
insert
facial
cosmet
filler
lesion
regress
month
withdraw
agent
man
took
ribavirin
interferon
alfa
week
develop
widespread
subcutan
nodul
leg
elbow
groin
month
complet
therapi
skin
biopsi
show
epithelioid
granuloma
consist
sarcoidosi
ct
scan
show
paratrach
subcarin
hilar
adenopathi
serum
ace
calcium
elev
symptom
radiograph
evid
sarcoidosi
resolv
year
without
treatment
man
develop
rheumatoid
arthriti
month
complet
cours
ribavirin
peginterferon
chronic
hepat
c
symmetr
eros
polyarthr
wrist
metacarpophalang
joint
requir
longterm
treatment
methotrex
sulfasalazin
man
take
ribavirin
pegyl
interferon
hepat
c
percentag
progress
spermatozoa
number
motil
sperm
per
ejacul
fell
treatment
round
cellspermatozoa
ratio
measur
abnorm
spermatogenesi
rose
return
baselin
month
later
sperm
dna
fragment
index
increas
markedli
treatment
month
still
rais
month
later
men
chronic
hepat
c
infect
receiv
peginterferon
ribavirin
ribavirin
concentr
higher
semin
fluid
serum
abnorm
spermatozoa
asthenoteratozoospermia
n
asthenozoospermia
n
teratozoospermia
n
common
baselin
sperm
densiti
percentag
motil
percentag
sperm
normal
morpholog
fell
antivir
therapi
vogtkoyanagiharada
diseas
diseas
melanocytecontain
organ
character
uveiti
poliosi
vitiligo
mening
also
known
uveodermatolog
syndrom
thought
due
helper
cellmedi
autoimmun
associ
interferon
alfa
ribavirin
two
men
chronic
hepat
c
infect
suscept
factor
bacteri
infect
studi
patient
coinfect
hiv
hepat
c
viru
take
pegyl
interferon
without
ribavirin
bacteri
infect
patient
receiv
least
one
dose
studi
medic
two
case
pyelonephr
one
case
prostat
escherichia
coli
one
case
diarrhea
klebsiella
oxytoca
two
septicemia
one
due
salmonella
enterica
one
staphylococcu
aureu
one
case
streptococcu
pneumonia
mening
eight
lower
respiratori
tract
infect
two
patient
one
case
sinus
two
case
cellul
factor
independ
associ
risk
bacteri
infect
relat
durat
hepat
c
infect
marker
liver
fibrosi
neutropenia
characterist
hiv
infect
includ
cell
count
yearold
man
splenectomi
age
year
immun
streptococcu
pneumonia
develop
pneumococc
mening
take
interferon
ribavirin
chronic
hepat
c
similar
case
report
woman
fatal
outcom
ribavirin
categori
x
product
us
fda
classif
contraind
women
may
becom
pregnant
also
contraind
men
whose
partner
may
becom
pregnant
us
ribavirin
pregnanc
registri
surveil
system
exposur
ribavirin
pregnanc
within
month
treatment
stop
reli
patient
healthcar
provid
provid
voluntari
outcom
data
ribavirin
teratogen
embryotox
laboratori
anim
given
pregnant
women
concern
express
safeti
peopl
room
patient
treat
ribavirin
aerosol
particularli
women
childbear
age
howev
ribavirin
detect
urin
plasma
erythrocyt
nurs
expos
ribavirin
administ
via
ventil
oxygen
tent
oxygen
hood
day
voluntari
ribavirin
pregnanc
registri
establish
monitor
pregnanc
exposur
ribavirin
evalu
potenti
human
teratogen
prenat
exposur
document
pregnant
women
expos
ribavirin
pregnanc
month
concept
either
directli
take
ribavirin
indirectli
sexual
contact
man
take
ribavirin
five
year
live
birth
direct
exposur
live
birth
indirect
exposur
document
includ
six
case
birth
defect
three
direct
exposur
three
indirect
among
liveborn
infant
two
case
torticolli
one
hypospadia
polydactyli
neonat
tooth
dehydrogenas
defici
ventricular
septal
defect
cyst
fourth
ventricl
brain
studi
singlenucleotidepolymorph
adult
take
ribavirin
peginterferon
rapid
fall
hemoglobin
concentr
initi
week
treatment
patient
genotyp
cc
inosin
triphosph
pyrophosphatas
itpa
gene
hemoglobin
concentr
genotyp
cc
patient
stabil
week
fall
similarli
patient
take
telaprevir
ribavirin
interferon
fall
hemoglobin
highest
genotyp
cc
itpa
gene
week
although
outcom
end
treatment
record
clearanc
ribavirin
impair
patient
renal
dysfunct
remov
hemodialysi
therefor
recommend
patient
creatinin
clearanc
mlminut
howev
hepat
c
infect
associ
renal
complic
membranoprolif
glomerulonephr
without
cryoglobulinemia
membran
glomerulonephr
focal
segment
glomerulosclerosi
seven
patient
treat
interferon
six
becam
hcvrna
pcr
neg
four
maintain
virolog
renal
remiss
one
maintain
virolog
partial
renal
remiss
ribavirininduc
anemia
manag
five
patient
lowdos
iron
erythropoietin
author
conclud
ribavirin
use
reason
safeti
hcvrelat
vascul
glomerulonephr
irrespect
renal
function
transient
acantholyt
dermatosi
grover
diseas
first
describ
grover
prurit
selflimit
popular
papulovesicular
erupt
mainli
distribut
trunk
white
middleag
men
histopatholog
hallmark
suprabas
acantholysi
differ
level
epidermi
origin
uncertain
case
relat
sunlight
heat
sweat
grover
diseas
attribut
ribavirin
yearold
man
chronic
hepat
c
present
prurit
papular
erupt
trunk
last
week
multipl
erythemat
excori
papul
neck
trunk
upper
arm
thigh
lesion
appear
week
combin
therapi
oral
ribavirin
subcutan
interferon
previous
treat
interferon
alfa
alon
dosag
withdraw
ribavirin
lesion
gradual
fade
return
week
reintroduct
intracellular
triphosphoryl
pharmacokinet
lamivudin
stavudin
zidovudin
assess
patient
coinfect
human
immunodefici
viru
hepat
c
viru
receiv
peginterferon
microgramsweek
plu
either
placebo
ribavirin
mgday
differ
retrospect
review
medic
record
eight
patient
develop
sever
pancytopenia
administr
azathioprin
interferon
alfa
ribavirin
bone
marrow
suppress
reach
nadir
mean
interv
week
time
mean
platelet
count
l
mean
hemoglobin
g
dl
mean
neutrophil
count
l
normal
thiopurin
methyltransferas
genotyp
two
patient
azathioprin
metabolit
measur
myelotox
accompani
rais
total
methyl
metabolit
concentr
reduc
nucleotid
concentr
pegyl
interferon
alfa
ribavirin
withdrawn
full
blood
count
return
normal
recurr
peginterferon
reintroduc
ribavirin
azathioprin
alon
author
conclud
combin
inosin
monophosph
dehydrogenas
inhibitor
purin
analogu
avoid
anoth
similar
case
report
interact
warfarin
ribavirin
report
white
man
chronic
hepat
c
took
interferon
plu
ribavirin
dosag
warfarin
increas
mgweek
order
maintain
desir
degre
anticoagul
effect
reproduc
rechalleng
ribavirin
mechan
suppos
interact
known
exampl
ribavirin
clear
intracellular
phosphoryl
metabolit
kidney
warfarin
cyp
isoenzym
liver
warfarin
highli
protein
bound
ribavirin
howev
effect
warfarin
absorpt
action
clot
factor
synthesi
possibl
multisystem
organ
dysfunct
lactic
acidemia
occur
two
patient
hiv
hepat
c
infect
receiv
interferon
alfa
didanosin
ribavirin
coadministr
didanosin
ribavirin
lead
increas
toxic
secondari
rais
intracellular
concentr
phosphoryl
didanosin
thu
evid
suggest
combin
didanosin
plu
ribavirin
increas
risk
lactic
acidosi
random
studi
patient
coinfect
human
immunodefici
viru
hiv
hepat
c
hcv
given
interferon
togeth
either
full
cours
ribavirin
placebo
week
follow
ribavirin
patient
group
also
took
haart
took
zidovudin
significantli
patient
took
full
cours
ribavirin
reduc
dose
ribavirin
anemia
versu
also
took
zidovudin
took
full
cours
ribavirin
reduc
dose
ribavirin
reason
versu
anemia
versu
zidovudin
nucleosid
analogu
associ
significantli
lower
hemoglobin
concentr
versu
gdl
significantli
larger
fall
versu
gdl
howev
pronounc
associ
leukopenia
neutropenia
zidovudin
combin
zidovudin
interferon
ribavirin
avoid
possibl
hb
concentr
fals
reduc
joint
ribavirin
peginterferon
therapi
man
type
diabet
mellitu
treatment
withdrawn
hb
return
baselin
manag
epoetin
alfa
danazol
anemia
therapi
interferon
ribavirin
report
yearold
africanamerican
man
chronic
hepat
c
initi
given
subcutan
interferon
mu
three
timesweek
oral
ribavirin
mgday
pretreat
hemoglobin
gdl
good
therapeut
respons
hemoglobin
fell
firstli
gdl
gdl
week
prompt
reduct
dosag
ribavirin
mgday
hemoglobin
rose
gdl
antivir
therapi
withdrawn
week
reintroduc
month
later
relaps
given
subcutan
peginterferon
microgramsweek
oral
ribavirin
mgday
plu
subcutan
epoetin
alfa
uweek
prevent
anemia
therefor
need
reduc
dose
ribavirin
serum
hemoglobin
start
second
cours
therapi
gdl
remain
stabl
throughout
first
week
therapi
howev
week
abrupt
fall
hemoglobin
gdl
ribavirin
immedi
withdrawn
dosag
peginterferon
reduc
dosag
epoetin
alfa
increas
uweek
week
hemoglobin
fell
gdl
peginterferon
withdrawn
week
hemoglobin
reach
nadir
gdl
requir
transfus
three
unit
pack
erythrocyt
patient
continu
requir
one
unit
blood
everi
week
despit
continu
epoetin
alfa
final
stop
week
erythropoietin
antibodi
becam
detect
week
peak
week
danazol
mg
bd
mg
bd
start
week
withdraw
epoetin
alfa
hemoglobin
becam
stabl
gdl
week
systemat
review
use
plasma
ribavirin
concentr
monitor
therapi
patient
chronic
hepat
c
studi
previous
publish
ninestep
decisionmak
algorithm
use
help
determin
whether
measur
warrant
studi
support
other
refut
use
ribavirin
measur
methodolog
limit
small
sampl
size
retrospect
analys
lack
p
valu
adjust
multipl
analys
